Oncothyreon is currently conducting a Phase 1 clinical trial of PX-478 in patients with advanced metastatic cancer and a Phase 2 trial of PX-12 in patients with advanced pancreatic cancer. PX-866 is expected to enter a Phase 1 trial in patients with advanced cancers in the second quarter of 2008.
Details regarding these abstracts are as follows:
PX-478
- Molecular-genetic image guided studies of the antitumor HIF-1alpha inhibitor PX-478 in combination with radiation Abstract # 2566, Session: Novel Mechanisms of Drug Action Presentation: Monday, April 14, 2008, 2:55 p.m. to 3:10 p.m. P.T.
- HIF-1alpha antagonism by PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice Abstract # 1440, Session: mTOR/Akt/PI3K Inhibitors and Vascular/Hypoxia Targeting Agents Poster session: Sunday, April 13, 2008, 1:00 p.m. to 5:00 p.m. P.T.
PX-12
- Pharmacodynamic evaluation of plasma thioredoxin-1 for patient enrichment of PX-12 clinical trials Abstract # 4453, Session: Molecular Signatures and Proteomic Biomarkers Poster Session: Tuesday, April 15, 2008, 1:00 p.m. to 5:00 p.m. P.T.
PX-866
- Cellular and in vivo activity of a new PI3K inhibitor PX-866 for treatment of human glioblastoma Abstract # 3731, Session: Imaging in Preclinical and Clinical Therapeutics Poster Session: Tuesday, April 15, 2008, 8:00 a.m. to 12:00 p.m. PT
- Identification of novel synergistic targets RACK-1 and galectin-1 for rational drug combinations with PI3 Kinase inhibitors using siRNA synthetic lethality screening Abstract # 2761, Session: Signal Transduction and Therapeutics Poster Session: Monday, April 14, 2008, 1:00 p.m. to 5:00 p.m. P.T.
- Phosphatidylinositol 3-kinase stimulates the proliferation of bronchioalveolar stem cells in mouse models of oncogenic K-ras- induced lung cancer Abstract # 5408, Session: Stem Cells Poster Session: Wednesday, April 16, 2008, 8:00 a.m. to 12:00 p.m. P.T.
About Oncothyreon
Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.
Forward Looking Statements
In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to future clinical development plans for PX-12 and PX-866. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.
Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, and the safety and efficacy of PX-12 and PX-866. There can be no guarantee that the results of preclinical studies or of early clinical trials will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.
Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
Source: Oncothyreon Inc.
